Skip to main content Help with accessibility Skip to main navigation

Evolocumab

Red

Brand:

Repatha®

Nice TA:

394

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:
Cardiovascular system

Background

Evolocumab is recommended as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia, only if:
  • The dosage is 140 mg every 2 weeks.
  • Low-density lipoprotein concentrations are persistently above the thresholds specified in table 1 (see NICE TA 394) despite maximal tolerated lipid-lowering therapy. That is, either the maximum dose has been reached, or further titration is limited by intolerance (as defined in NICE’s guideline on familial hypercholesterolaemia).
  • The company provides evolocumab with the discount agreed in the patient access scheme.
    This guidance is not intended to affect the position of patients whose treatment with evolocumab was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

Red
Red
Red
Red
Red
Red
Red
Red
What do the colours mean?

Last Updated: 01 - Jul - 2016